BIOVANCE®
Human Amniotic Membrane Allograft
A Celularity Innovation

Real-world Experience With a Decellularized Dehydrated Human Amniotic Membrane Allograft: A Prospective, Observational, Multicenter Study of a Broad Patient Population in All Wound Types. Wounds 2015;27(6):158-169

Janice M. Smiell, MD[a]; Terry Treadwell, MD[b]; Helen D. Hahn, RN, MBA[a]; Michel H. Hermans, MD[c]

The aim of this observational study was to gain experience in the use and performance of BIOVANCE® versus standard of care (SOC) in a real-world wound population. **A broad range of partial and full thickness wounds were studied across a mix of patient types.**

- Eligibility for inclusion included any patient that would benefit from treatment
- Unlike other chronic wound prospective, randomized, controlled trials, there were no limits on patients' age, baseline wound size or co-existing conditions
- Key comorbidities included: arterial insufficiency, autoimmune disease, diabetes, and edema/lymphedema

BIOVANCE SUPPORTS WOUND CLOSURE ACROSS A VARIETY OF WOUND AND PATIENT TYPES

BIOVANCE: at 8 weeks

100%
Wounds < 3.12 cm

50%
Wounds > 13.13 cm

2X BIOVANCE closed nearly twice as many wounds as control

SOC: at 12 weeks

24-34%
(average baseline)

The authors concluded that a longer observation time may have resulted in closure of the larger wounds.

[a] Alliqua Biomedical, Inc., Langhorne, PA
[b] Institute for Advanced Wound Care, Montgomery, AL
[c] Hermans Consulting Inc, Newtown, PA

celularity®

CASE STUDIES OF PATIENTS IN THIS STUDY

CASE STUDY 1: VENOUS STASIS ULCER

Patient	Comorbidities	Baseline Wound Size	Closure
• 61 year old female with 3 prior treatment failures	• Peripheral vascular disease • Venous insufficiency • Immuno deficiency	1.8cm x 1.2cm x 0.2cm	7 weeks with 1 application



BASELINE



WEEK 7 CLOSED

Treatment Regimen:

- Burow's Solution was applied to the periwound area twice a day

CASE STUDY 2: ACUTE WOUND

Patient	Comorbidities	Baseline Wound Size	Closure
• 67 year old male with right BKA stump dehiscence	• Severe peripheral artery disease • Diabetes	7cm x 2.5cm x 0.1cm	6 weeks with 1 application



BASELINE



WEEK 6 CLOSED

Treatment Regimen:

- 1 application of BIOVANCE, not fenestrated
- Secondary dressing with nonadherent petroleum gauze and moist gauze

CASE STUDY 3: DIABETIC FOOT ULCER

Patient	Comorbidities	Baseline Wound Size	Closure
• 68 year old male with full thickness wound	• Type 2 DM, Chronic Renal Failure, Neuropathic, Lymphedema	12.9cm x 4.8cm x 0.1cm	25 weeks with 5 applications



BASELINE



WEEK 25 CLOSED

Treatment Regimen:

- Application of BIOVANCE on Days 1, 4, 16, 38 and136
- Secondary dressing during treatment with petroleum gauze, topical gentamicin, silver hydrofiber dressing, polyurethane foam with gauze and elastic wrap
- Patient placed on gentamicin at week 3 with positive cultures for *staphyloccus aureus*

CITATION: Data and photos provided by Terry Treadwell, MD, on file at Celularity.

celularity®